Gilead Sciences

GILD · Health Care · Market cap $161B

Q1 FY26 Mar 31, 2026 reported May 7, 2026

Revenue$7B +4% year over year

Gross profit$5.5B

Operating profit$2.6B

Net profit$2B 29% margin

Numbers and detail

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	7	100%	+4%
HIV Products Biktarvy	3.4	49%	+7%
Other	1.3	19%
Oncology Product	0.8	11%
Trodelvy	0.4	6%	+37%
Yescarta	0.3	4%	−14%
Liver Disease Products Sofosbuvir…	0.3	4%	−18%
HIV Products Genvoya	0.3	4%	−27%
Liver Disease Products Vemlidy	0.2	3%	−6%
Cost of revenue	−1.4	20%
Gross profit	5.5	79% margin	+2pp
SG&A	−1.4	21%	+2pp
Other	−1.5	21%	+0pp
Operating profit	2.6	37% margin	+4pp
Tax	−0.6
Net profit	2	29%	+9pp

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	7.8	100%	+3%
Biktarvy	3.7	47%
Other	1.4	18%
Descovy	0.7	9%
Total Cell Therapy	0.4	5%
Royalty, contract and other	0.4	5%
Genvoya	0.4	5%
Trodelvy	0.4	5%
Yescarta	0.3	4%
Cost of revenue	−1.6	21%
Gross profit	6.2	80% margin	+1pp
SG&A	−1.4	17%	−2pp
Other	−1.5	20%	+0pp
Operating profit	3.3	43% margin	+31pp
Tax	−0.5
Net profit	3.1	39%	+23pp

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	7.1	100%	+2%
HIV Products Biktarvy	3.5	49%	+9%
Other	1.1	15%
HIV Products Descovy	0.7	10%	+35%
Yescarta	0.4	6%	−5%
HIV Products Genvoya	0.4	6%	−14%
Trodelvy	0.4	6%	+14%
Liver Disease Products Sofosbuvir…	0.3	4%	−28%
HIV Products Odefsey	0.3	4%	−5%
Cost of revenue	−1.5	21%
Gross profit	5.6	79% margin	+1pp
SG&A	−1.4	19%	−1pp
Other	−1.7	25%	+0pp
Operating profit	2.5	35% margin	−3pp
Tax	−0.5
Net profit	2	28%	+4pp

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	6.7	100%	+0%
HIV Products Biktarvy	3.2	48%	+7%
Other	1.2	18%
HIV Products Descovy	0.6	9%	+38%
Yescarta	0.4	6%	+2%
HIV Products Genvoya	0.4	6%	−10%
Liver Disease Products Sofosbuvir…	0.3	4%
Veklury	0.3	4%
Trodelvy	0.3	4%	−5%
Cost of revenue	−1.5	22%
Gross profit	5.1	77% margin	+0pp
SG&A	−1.3	19%	−2pp
Other	−1.6	24%	+0pp
Operating profit	2.2	34% margin	+98pp
Tax	−0.3
Interest & other costs	−0.6
Net profit	1.3	20%	+82pp

Quarter by quarter

Pick a quarter and the diagram above changes. Bars compare revenue across the quarters we hold.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q1 FY26	Mar 31, 2026	May 7, 2026	$7B	+4%	37%	$2B	29%
Q3 FY25	Jul 1 – Sep 30, 2025	Nov 7, 2025	$7.8B	+3%	42%	$3.1B	39%
Q2 FY25	Apr 1 – Jun 30, 2025	Aug 7, 2025	$7.1B	+2%	35%	$2B	28%
Q1 FY25	Jan 1 – Mar 31, 2025	May 7, 2025	$6.7B	+0%	33%	$1.3B	20%